Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer.
Saved in:
| Title: | Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer. |
|---|---|
| Authors: | Liu D; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia., Wong-Brown M; Equity in Health and Wellbeing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia., Sarker FA; Translational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia., Matthews B; Equity in Health and Wellbeing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia., Morrison J; Equity in Health and Wellbeing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.; School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia., Dickson KA; Translational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia., Alghalayini A; Translational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia., Stojanova J; Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney, Sydney, NSW, Australia., Wan KM; Gynaecological Oncology Department, Royal Hospital for Women, Sydney, NSW, Australia., Duggan J; Gynaecological Oncology Department, Royal Hospital for Women, Sydney, NSW, Australia., Loo C; Department of Anatomical Pathology, NSW Health Pathology, Prince of Wales Hospital, Sydney, NSW, Australia., Stannard G; Equity in Health and Wellbeing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia., Powell E; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia., Hodder B; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia., Barlow E; Gynaecological Cancer Research Group, School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW, Australia., Marsh DJ; Translational Oncology Group, School of Life Sciences, Faculty of Science, University of Technology Sydney, Sydney, NSW, Australia., Ford CE; Gynaecological Cancer Research Group, Lowy Cancer Research Centre and School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, NSW 2052, Australia., Bowden NA; School of Medicine and Public Health, College of Health, Medicine and Wellbeing, University of Newcastle, Newcastle, NSW 2308, Australia.; Equity in Health and Wellbeing Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, Australia. |
| Source: | Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2026 Jan 02; Vol. 18, pp. 17588359251409010. Date of Electronic Publication: 2026 Jan 02 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Sage Country of Publication: England NLM ID: 101510808 Publication Model: eCollection Cited Medium: Print ISSN: 1758-8340 (Print) Linking ISSN: 17588340 NLM ISO Abbreviation: Ther Adv Med Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1758-8340 |
|---|---|
| DOI: | 10.1177/17588359251409010 |
